DashboardAll companies
Run this on your own research
Healthcare · Biotechnology

Vertex Pharmaceuticals Inc.

VRTXNASDAQ$523.93−$11.24 (−2.10%)Market closed

Price Chart

Daily

Key facts

Market Cap
$132.92B
P/E
33.9x
P/B
7.18x
ROE
22.5%

Vertex Pharmaceuticals Inc.

Healthcare · Biotechnology · FY 2025

Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for its pioneering work in treating cystic fibrosis (CF), a genetic disorder that affects respiratory and digestive systems. Through its robust portfolio of CF-focused therapies, Vertex addresses a significant unmet medical need, improving the quality of life for patients worldwide. The company's research pipeline also includes promising treatments for other serious conditions, including sickle cell disease and beta thalassemia. Based in Boston, Massachusetts, Vertex Pharmaceuticals serves the global healthcare sector, collaborating with key industry players and academic institutions to advance its scientific initiatives. Its role in the biotechnology landscape is significant, both for its impact on patient outcomes and its contribution to advancing medical science through innovation and targeted therapeutic solutions.

CEO
Dr. Reshma Kewalramani FASN, M.D.
Employees
6,100
Website
vrtx.com

Company Statistics

Valuation

P/E
33.9x
P/B
7.18x
P/S
11.16x
EV/EBITDA
24.9x
P/FCF
41.9x

Margins

Gross
86.2%
EBITDA
43.7%
Operating
37.9%
Pre-Tax
38.7%
Net
32.9%

Returns

ROA
16.4%
ROE
22.5%
ROIC
19.3%

Growth (CAGR)

Rev 3Yr
10.4%
Rev 5Yr
14.1%
Op Inc 3Yr
1.4%
Net Inc 3Yr
6.0%

Financial Health

Cash & Cash Equivalents
$5.08B
Net Debt
$1.89B
Debt/Equity
37.4%
Interest Cov
—

Profile

Revenue
$12.00B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Vertex Pharmaceuticals Inc. (VRTX) Stock Forecast 2026 $523.93 — Price, Financials & Analyst Targets | AlphaLenz